ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
8.52
+0.27 (3.27%)
Mar 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.20 - 8.73
52 week 5.34 - 15.59
Open 8.31
Vol / Avg. 1.84M/1.31M
Mkt cap 710.39M
P/E     -
Div/yield     -
EPS -0.85
Shares 86.11M
Beta 1.84
Inst. own 82%
Apr 24, 2015
Q3 2015 ImmunoGen Inc Earnings Call - 8:00AM EDT - Add to calendar
Apr 24, 2015
Q3 2015 ImmunoGen Inc Earnings Release Add to calendar
Mar 2, 2015
ImmunoGen Inc at Cowen Health Care Conference - Webcast
Feb 24, 2015
ImmunoGen Inc at RBC Healthcare Conference
Feb 12, 2015
ImmunoGen Inc at Leerink Global Healthcare Conference
Jan 30, 2015
Q2 2015 ImmunoGen Inc Earnings Call - Webcast
Jan 30, 2015
Q2 2015 ImmunoGen Inc Earnings Release
Jan 13, 2015
ImmunoGen Inc at JPMorgan Healthcare Conference - Q&A Session - Webcast
Jan 13, 2015
ImmunoGen Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 28.23% -119.15%
Operating margin 28.53% -119.43%
EBITD margin - -111.75%
Return on average assets 40.27% -37.67%
Return on average equity 80.17% -72.25%
Employees 307 -
CDP Score - -

Address

830 WINTER ST
WALTHAM, MA 02451
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoGen, Inc. is a biotechnology company. The Company develops targeted anticancer therapeutics. The Company has three wholly-owned product candidates in clinical testing, with seven additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. The Company�s clinical-stage product candidates, include IMGN289, IMGN853 and IMGN529. IMGN289 compound is a treatment for many cases of head and neck cancers. IMGN853 compound is a potential treatment for epithelial ovarian cancer, endometrial cancer and other cancers. IMGN529 compound is used for the treatment of NHL (non-Hodgkin lymphoma). The Company�s IMGN529 ADC is a new treatment for cancers that express CD37, such as NHL and chronic lymphocytic leukemia.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Age: 59
Bio & Compensation  - Reuters
Richard J Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Distinguished Research Fellow
Age: 63
Bio & Compensation  - Reuters
Sandra E. Poole Senior Vice President - Technical Operations.
Age: 51
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
James J. O'Leary M.D. Vice President, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Peter J. Williams Vice President - Business Development
Age: 60
Bio & Compensation  - Reuters
Mark Goldberg Independent Director
Age: 60
Bio & Compensation  - Reuters